HK Stock Market Move | Biocytogen Pharmaceuticals-B (02315) surged over 13% as its core business maintained rapid growth in the first half of the year, with AI empowerment accelerating the realization of its platform.

Biocytogen Pharmaceuticals-B (02315) rose over 13%, and as of the time of writing, it is up 11.61%, priced at HKD 63.95, with a trading volume of HKD 103 million. In terms of news, thanks to the deep synergy of its "full human antibody library" and "targeted humanized mouse library" as dual engines, Biocytogen Pharmaceuticals has not only achieved a comprehensive leap in revenue and profit but has also maintained profitability for five consecutive quarters. In the first half of this year, the company realized revenue of CNY 940 million, a year-on-year increase of 51.6%; the net profit attributable to shareholders reached CNY 240 million, a year-on-year increase of 402%. During the reporting period, the total revenue from the preclinical segment was CNY 723 million, up 57.9% year-on-year, with sales of innovative animal models generating CNY 446 million, a year-on-year increase of 62.4%, and a gross profit margin of 82.3%. The antibody development business achieved revenue of CNY 218 million, a year-on-year increase of 33.8%, while maintaining a high gross profit margin of 92.8%. The company signed over 105 new cooperation agreements, bringing the total number of drug cooperation development/authorization/transfer agreements to 455, of which more than 150 were newly signed, involving over 150 cooperating pharmaceutical companies, with a total disclosed transaction amount reaching hundreds of billions. Meanwhile, leveraging its extensive library of over one million real human antibody sequence molecules, the company has preliminarily developed the RenSuper Workstation, marking the transition of antibody drug research and development from the previous lengthy "idea - candidate - validation" process to the intelligent era of "one-click drug development."